OBJECTIVES: To describe the long-term clinical and morphological outcome of symptomatic hepatic cysts treated with percutaneous ethanol sclerotherapy (PES). METHODS: From December 2003 to September 2011, all patients with hepatic cysts undergoing PES with a follow-up after 12 months were included. Evolution of the volume of the cysts and clinical and biological data were recorded. Features of the cyst were evaluated in each patient: simple, haemorrhagic or developed on underlying polycystic liver disease (PCLD). RESULTS: Fifty-eight cysts (median volume 666 mL) were treated in 57 patients (52 women, mean age 58 years (18-80)). Twenty-two patients (39 %) had simple hepatic cysts, 19 (33 %) had dominant cysts on PCLD and 20 had haemorrhagic cysts (34.5 %), including 4 with PCLD. After a mean 27.3 months of follow-up, the final median cystic volume was 13.5 mL (p < 0.0001), and the median reduction in cyst volume was 94 % (58-100 %). Treatment was satisfactory in 95 % of the patients (54/57) (symptoms disappeared in 45/57 (79 %), decreased in 9/57 (16 %)). There was no clinical or morphological difference between patients with PCLD, haemorrhagic cysts or simple cysts. CONCLUSION: The clinical and morphological efficacy of a single session of PES is very high, regardless of the presence of intracystic haemorrhage or underlying PCLD. KEY POINTS: • The clinical efficacy of percutaneous ethanol sclerotherapy is very high. • Haemorrhagic content should not be a contraindication for percutaneous sclerotherapy. • Dominant cysts on polycystic liver disease should be treated with PES. • Imaging follow-up should not be performed shortly after the procedure.
OBJECTIVES: To describe the long-term clinical and morphological outcome of symptomatic hepatic cysts treated with percutaneous ethanol sclerotherapy (PES). METHODS: From December 2003 to September 2011, all patients with hepatic cysts undergoing PES with a follow-up after 12 months were included. Evolution of the volume of the cysts and clinical and biological data were recorded. Features of the cyst were evaluated in each patient: simple, haemorrhagic or developed on underlying polycystic liver disease (PCLD). RESULTS: Fifty-eight cysts (median volume 666 mL) were treated in 57 patients (52 women, mean age 58 years (18-80)). Twenty-two patients (39 %) had simple hepatic cysts, 19 (33 %) had dominant cysts on PCLD and 20 had haemorrhagic cysts (34.5 %), including 4 with PCLD. After a mean 27.3 months of follow-up, the final median cystic volume was 13.5 mL (p < 0.0001), and the median reduction in cyst volume was 94 % (58-100 %). Treatment was satisfactory in 95 % of the patients (54/57) (symptoms disappeared in 45/57 (79 %), decreased in 9/57 (16 %)). There was no clinical or morphological difference between patients with PCLD, haemorrhagic cysts or simple cysts. CONCLUSION: The clinical and morphological efficacy of a single session of PES is very high, regardless of the presence of intracystic haemorrhage or underlying PCLD. KEY POINTS: • The clinical efficacy of percutaneous ethanol sclerotherapy is very high. • Haemorrhagic content should not be a contraindication for percutaneous sclerotherapy. • Dominant cysts on polycystic liver disease should be treated with PES. • Imaging follow-up should not be performed shortly after the procedure.
Authors: A Regev; K R Reddy; M Berho; D Sleeman; J U Levi; A S Livingstone; D Levi; U Ali; E G Molina; E R Schiff Journal: J Am Coll Surg Date: 2001-07 Impact factor: 6.113
Authors: J F Gigot; M Legrand; G Hubens; L de Canniere; E Wibin; F Deweer; M L Druart; C Bertrand; H Devriendt; R Droissart; M Tugilimana; P Hauters; L Vereecken Journal: World J Surg Date: 1996-06 Impact factor: 3.352
Authors: Zhi Ven Fong; Andrea M Wolf; Cataldo Doria; Adam C Berger; Ernest L Rosato; Francesco Palazzo Journal: J Gastrointest Surg Date: 2012-06-12 Impact factor: 3.452
Authors: Qi Qian; Airong Li; Bernard F King; Patrick S Kamath; Donna J Lager; John Huston; Clarence Shub; Sonia Davila; Stefan Somlo; Vicente E Torres Journal: Hepatology Date: 2003-01 Impact factor: 17.425
Authors: Titus F M Wijnands; Tom J G Gevers; Marten A Lantinga; René H Te Morsche; Leo J Schultze Kool; Joost P H Drenth Journal: Eur Radiol Date: 2018-01-09 Impact factor: 5.315
Authors: Myrte K Neijenhuis; Titus F M Wijnands; Wietske Kievit; Maxime Ronot; Tom J G Gevers; Joost P H Drenth Journal: Eur Radiol Date: 2018-12-12 Impact factor: 5.315
Authors: Titus F M Wijnands; Maxime Ronot; Tom J G Gevers; Julie Benzimra; Leo J Schultze Kool; Valérie Vilgrain; Joost P H Drenth Journal: Eur Radiol Date: 2016-05-14 Impact factor: 5.315
Authors: Titus Fm Wijnands; Bastian Schoenemeier; Andrej Potthoff; Tom Jg Gevers; Hans Groenewoud; Michael J Gebel; Kinan Rifai; Michael P Manns; Joost Ph Drenth Journal: United European Gastroenterol J Date: 2018-03-08 Impact factor: 4.623